NASDAQ$ZLAB
Zai Lab Limited-ADR · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
Reported a revenue increase driven by ZEJULA® growth and pipeline expansion.
Zai Lab reported a 36% year-over-year increase in total product revenue, reaching $62.8 million for the first quarter of 2023. The company highlighted the expansion of its lung cancer franchise and global oncology pipeline, along with a strong cash position of $931.4 million.
- Total product revenue reached $62.8 million, a 36% increase year-over-year.
- ZEJULA® sales grew by 44% year-over-year.
- Expanded lung cancer franchise with a next-generation antibody-drug conjugate (ADC) program (ZL-1310).
- Cash position remained strong at $931.4 million as of March 31, 2023.
Headline financials
Revenue & EPS history
Zai Lab · Revenue · Quarterly
$62.8M
Revenue by segment
Zai Lab · $48.2M total across 2 segments · Q1 2023
- ZEJULA$42.7M+44.3%88.6%
- NUZYRA$5.5M+685.7%11.4%
Forward guidance
Zai Lab is focused on strategic priorities including regulatory approvals for efgartigimod, initiating studies for KarXT and bemarituzumab, and advancing its proprietary pipeline.
Tailwinds
- Potential BLA approval and commercial launch by the NMPA for efgartigimod alfa injection for the treatment of adult patients with gMG in China.
- Potential BLA submission to the NMPA for SC efgartigimod for the treatment of adult patients with gMG in China in mid-2023.
- Zai Lab to join the global Phase 3 FORTITUDE-101 study in first-line gastric cancer in China in mid-2023.
- Zai Lab to join the global Phase 3 FORTITUDE-102 study in first-line gastric cancer in China.
- Zai Lab to initiate a bridging study for KarXT for the treatment of patients with schizophrenia in China in mid-2023.
Headwinds
- Risks related to commercializing approved products.
- Risks associated with obtaining funding for operations.
- Uncertainties in clinical and pre-clinical development.
- Potential delays in regulatory approvals.
- Impact of the COVID-19 pandemic on business operations.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2023
-0.1%
Avg return
Earnings day
+0.3%
Avg return
5 days after
-0.5%
Avg return
30 days after
45%
13 / 29 earnings
Positive
+26.0%
Q1 2024
Best reaction
-11.2%
Q2 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -5.9% | -7.0% | -20.9% | |
| Q4 2025 | +1.7% | -8.6% | -7.2% | |
| Q3 2025 | -6.4% | -11.3% | -21.4% | |
| Q1 2025 | +2.5% | +0.9% | +34.4% | |
| Q4 2024 | -2.0% | -3.1% | +6.3% | |
| Q3 2024 | -3.7% | -13.0% | -14.1% | |
| Q2 2024 | -5.6% | -7.8% | +11.3% | |
| Q1 2024 | +26.0% | +29.0% | +19.9% | |
| Q4 2023 | -0.9% | +0.5% | -23.7% | |
| Q3 2023 | +7.4% | +0.9% | -1.5% | |
| Q2 2023 | -11.2% | -5.4% | +3.5% | |
| Q1 2023 | +1.4% | -9.3% | -24.2% | |
| Q4 2022 | -0.6% | +7.3% | -10.5% | |
| Q3 2022 | +1.9% | +23.9% | +18.7% | |
| Q2 2022 | -5.0% | -6.2% | -8.0% | |
| Q1 2022 | -2.1% | +30.0% | +5.6% | |
| Q4 2021 | -4.0% | -26.0% | -19.6% | |
| Q3 2021 | +0.7% | -2.3% | -22.3% | |
| Q2 2021 | +0.6% | +0.9% | +0.4% | |
| Q1 2021 | -5.1% | -3.3% | +8.3% | |
| Q4 2020 | +0.3% | -7.0% | -9.6% | |
| Q4 2019 | -1.4% | -2.7% | +17.0% | |
| Q1 2020 | -8.7% | +3.1% | +18.3% | |
| Q2 2019 | +4.3% | +4.1% | -4.0% | |
| Q1 2019 | +3.7% | +6.7% | -9.7% | |
| Q4 2018 | +10.4% | +10.4% | +1.6% | |
| Q3 2018 | +6.7% | +13.6% | +13.1% | |
| Q4 2017 | -5.3% | -8.8% | +22.8% | |
| Q3 2017 | -2.2% | -0.6% | +0.3% | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro